The new collaborative research agreement between Teva Pharmaceutical Industries and AbCellera will allow to exploit the high-throughput single cell antibody platform for the discovery of rare monoclonal antibodies. Under the terms of the agreement, AbCellera will receive an upfront payment, research payments, and is eligible to receive undisclosed downstream milestones associated with the development and approval of therapeutic antibodies.
“This agreement will be complementary to our existing antibody discovery process with the potential to strengthen Teva’s capabilities in novel biologics discovery”, said Michael Hayden (photo), president of Global R&D and chief scientific officer at Teva.
